New spesolimab data showed significant improvement in patients with generalized pustular psoriasis (GPP) flares

Efficacy and safety data from the Effisayil™ 1 trial presented at AAD 2022 showed spesolimab is associated with rapid pustular and skin clearance ...

Related Keywords

Boston ,Massachusetts ,United States ,American ,Boni Elewski ,Prnewswire Boehringer Ingelheim ,Matt Frankel ,Boehringer Ingelheim Pharmaceuticals ,Boehringer Ingelheim ,Drug Administration ,American Academy Of Dermatology ,Animal Health ,Department Of Dermatology ,University Of Alabama School Medicine ,Clinical Development ,Annual Meeting ,New England Journal ,Alabama School ,Vice President ,Medical Affairs ,Specialty Care ,Biologics License Application ,Priority Review ,Orphan Drug Designation ,Breakthrough Therapy Designation ,Ingelheim Immunology ,Pioneering Science ,Human Pharma ,Biopharmaceutical Contract ,